ES2185357T3 - Compuestos 2-sustituidos-1-piperidil bencimidazol como agonistas del receptor orl1. - Google Patents
Compuestos 2-sustituidos-1-piperidil bencimidazol como agonistas del receptor orl1.Info
- Publication number
- ES2185357T3 ES2185357T3 ES99926688T ES99926688T ES2185357T3 ES 2185357 T3 ES2185357 T3 ES 2185357T3 ES 99926688 T ES99926688 T ES 99926688T ES 99926688 T ES99926688 T ES 99926688T ES 2185357 T3 ES2185357 T3 ES 2185357T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halo
- aromatic
- group
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 title 1
- 102100028646 Nociceptin receptor Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 14
- -1 halo (C1-C4) alkyl Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 abstract 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004385 trihaloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de la siguiente fórmula: o una sal del mismo, en la que R se selecciona entre el grupo formado por: cicloalquilo(C3-C11), bicicloalquilo(C6-C16), tricicloalquilo(C6-C16) y tetracicloalquilo(C8-C16) en los que dichos grupos son parcialmente saturados, totalmente saturados o totalmente insaturados y son opcionalmente sustituidos con hasta tres sustituyentes escogidos independientemente entre el grupo formado por: halo, hidroxi, alquilo(C1-C5) y cicloalquilo(C3-C7); A está unido al átomo de carbono de R con el que R se une al átomo de nitrógeno del anillo de piperidina, y se selecciona entre el grupo formado por: alquilo(C1-C7), mono-, di- o tri-halo alquilo(C1-C7), alquenilo(C2-C5), alquinilo(C2-C5), fenil-alquilo(C1-C5), arilo, y heterocíclicos aromáticos y no aromáticos que comprendan de cuatro a diez átomos en el anillo, en donde de uno a cuatro átomos del anillo se seleccionan independientemente entre heteroátomos, y siendo dicha fracción fenilo en fenil-alquilo(C1-C5), arilo, o heterocíclicos aromáticos o no aromáticos siendo opcionalmente sustituida con hasta tres sustituyentes escogidos independientemente entre el grupo formado por: halo, hidroxi, alquilo(C1-C4), halo- alquilo(C1-C4), alcoxi(C1-C4), halo-alcoxi(C1-C4), alquil(C1-C4)¿CO-, fenilo, bencilo, -CHO, ciano, alquil(C1- C4)¿CO-, NH2-CO-, NH2-CH2-, amino, alquil(C1-C4)¿NH-, di(alquil(C1-C4))-N-, alquil(C1-C4)¿CO-NH-, alquil(C1-C4)- NH¿CO-, hidracino, azido, ureido, amidino, guanidino, oxo y =N-OH; Y se selecciona entre el grupo formado por: hidrógeno, halo, amino, mercapto, alquil(C1-C12)¿M-, cicloalquil(C3-C7)¿M-, alquenilo(C2-C6)¿M-, arilo-M, heterocíclicos-M- aromáticos o no aromáticos, aril- alquil(C1-C5)-M-, heterocíclicos-alquil(C1-C5)-M- aromáticos o no aromáticos, comprendiendo dicha fracción heterocíclica aromática o no aromática de dichos grupos de cuatro adiez átomos en el anillo, en donde de uno a cuatro átomos del anillo se seleccionan independientemente entre heteroátomos (es decir, O, S y N), y M se selecciona entre el grupo formado por un enlace covalente, O, S, SO, SO2, CO (es decir, C(=O)), NQ (es decir, N(Q)), NQCO (es decir, N(Q)C(=O)), CONQ (es decir, C(=O)N(Q)), en donde Q se selecciona entre el grupo formado por hidrógeno y alquilo(C1-C6), siendo dicha fracción alquilo(C1-C12), cicloalquilo(C3-C7) o alquenilo(C2-C6) opcionalmente sustituida en dichos grupos con hasta tres (preferiblemente de cero a dos) sustituyentes escogidos independientemente entre el grupo formado por: halo, hidroxi, amino, alquilo(C1-C4), halo-alquil(C1-C4)-NH-, di- alquil(C1-C4)-N-, hidracino, azido, ureido, amidino, guanidino, alcoxi(C1-C4), alquil(C1-C4)-S-, alquil(C1-C4)- SO-, y alquil(C1-C4)-SO2-, y siendo dicha fracción arilo o heterocíclica aromática o no aromática de dichos grupos opcionalmente sustituida con hasta tres sustituyentes escogidos independientemente entre el grupo formado por: halo, hidroxi, alquilo(C1-C4), halo-alquilo(C1-C4), alcoxi(C1-C4), halo-alcoxi(C1-C4), alquil(C1-C4)¿CO-, fenilo, bencilo, -CHO, ciano, alquil(C1-C4)¿CO-, NH2-CO-, NH2-CH2-, amino, alquil(C1-C4)¿NH-, di-alquil(C1-C4)-N-, alquil(C1-C4)¿CO-NH-, alquil(C1-C4)-NH¿CO-, hidracino, azido, ureido, amidino, guanidino, oxo y =N-OH; y Z1, Z2, Z3 y Z4 se seleccionan independientemente entre el grupo formado por: hidrógeno, halo, alquilo(C1- C4), halo-alquilo(C1-C4), alcoxi(C1-C4), alquil(C1-C4)- sulfonilo, alquil(C1-C4)-CO-, carboxi, alquil(C1-C4)-COO-, amino, NH2CO-, alquil(C1-C4)-CO-NH-, alquil(C1-C4)-SO2-NH- , fenilo y naftilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB98/01206 | 1998-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2185357T3 true ES2185357T3 (es) | 2003-04-16 |
Family
ID=11004738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99926688T Expired - Lifetime ES2185357T3 (es) | 1998-08-06 | 1999-07-05 | Compuestos 2-sustituidos-1-piperidil bencimidazol como agonistas del receptor orl1. |
Country Status (44)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340681B1 (en) * | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| DE60023100T2 (de) * | 2000-01-05 | 2006-07-06 | Pfizer Inc. | Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| AU2403802A (en) | 2000-11-15 | 2002-05-27 | Banyu Pharma Co Ltd | Benzimidazole derivatives |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| ES2323876T3 (es) | 2001-04-18 | 2009-07-27 | Euro-Celtique S.A. | Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor. |
| EP1975164B1 (en) * | 2001-04-18 | 2010-01-27 | Euro-Celtique S.A. | Octahydrobenzimidazolone compounds as analgetics |
| UA74439C2 (uk) | 2001-04-18 | 2005-12-15 | Еро-Селтік, С.А. | Сполуки спіропіразолу |
| JP4489354B2 (ja) | 2001-04-18 | 2010-06-23 | ユーロ−セルティーク エス．エイ． | スピロインデンおよびスピロインダン化合物類 |
| MXPA03009602A (es) | 2001-04-18 | 2004-04-02 | Euro Celtique Sa | Analogos de nociceptina. |
| EP1406629A1 (en) * | 2001-07-02 | 2004-04-14 | Omeros Corporation | Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| US20030040479A1 (en) * | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
| SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| AU2002360561A1 (en) * | 2001-12-11 | 2003-06-23 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| US7566728B2 (en) | 2002-03-29 | 2009-07-28 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| DE10252665A1 (de) | 2002-11-11 | 2004-06-03 | Grünenthal GmbH | 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate |
| DE10252666A1 (de) | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| GB0315203D0 (en) * | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| US8067603B2 (en) | 2003-09-25 | 2011-11-29 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |
| GB0328243D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US20050228023A1 (en) * | 2003-12-19 | 2005-10-13 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| JPWO2006038738A1 (ja) * | 2004-10-08 | 2008-05-15 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| JP2008526815A (ja) | 2005-01-11 | 2008-07-24 | ノイロサーチ アクティーゼルスカブ | 低コンダクタンスのカルシウム依存性カリウムチャネルのモジュレーターとしての新規２−アミノベンゾイミダゾール誘導体及びそれらの使用 |
| AU2007271243A1 (en) * | 2006-07-03 | 2008-01-10 | Neurosearch A/S | Combinations of monoamine reuptake inhibitors and potassium channel activators |
| CA2675419C (en) * | 2007-01-16 | 2013-11-12 | Purdue Pharma L.P. | Heterocyclic-substituted piperidine compounds and the uses thereof |
| KR20120102172A (ko) * | 2007-08-31 | 2012-09-17 | 시오노기세이야쿠가부시키가이샤 | 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도 |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| BRPI0911031B8 (pt) | 2008-07-21 | 2021-05-25 | Purdue Pharma Lp | compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes |
| CN103168032A (zh) | 2010-08-05 | 2013-06-19 | 安美基公司 | 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物 |
| US9169203B2 (en) | 2012-01-06 | 2015-10-27 | Novus International, Inc. | Sulfoxide-based surfactants |
| WO2013119955A1 (en) | 2012-02-09 | 2013-08-15 | Novus International Inc. | Functionalized polymer compositions |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| CN107753462B (zh) | 2012-07-12 | 2021-01-08 | 诺华丝国际股份有限公司 | 用于保护生物活性剂的基质和层组合物 |
| US9085561B2 (en) * | 2012-07-30 | 2015-07-21 | Purdue Pharma L.P. | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators |
| WO2014102594A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| US10005765B2 (en) | 2014-03-20 | 2018-06-26 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
| EP3374428A4 (en) | 2015-11-12 | 2019-06-05 | Novus International Inc. | SULFUR COMPOUNDS AS SOLVENTS |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318900A (en) * | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| JPS5297978A (en) * | 1976-06-02 | 1977-08-17 | Yoshitomi Pharmaceut Ind Ltd | Preparation of alicyclic derivatives |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| WO1997007208A1 (en) | 1995-08-15 | 1997-02-27 | Universite Libre De Bruxelles | Nucleic acid molecules encoding peptides having pronociceptive properties |
| US5866346A (en) | 1995-09-27 | 1999-02-02 | Indiana Unversity Foundation | Methods of using dynorphins as ligands for XOR1 receptor |
| EP0898568B1 (en) * | 1996-04-19 | 2006-10-04 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| EP0813065A3 (en) | 1996-06-13 | 1998-07-22 | F. Hoffmann-La Roche Ag | Modulation of LC132 (opioid-like) receptor function |
| EP0829481A1 (en) * | 1996-09-16 | 1998-03-18 | Pfizer Inc. | Morphinan hydroxamic acid compounds |
| US5718912A (en) * | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| EP0990653B1 (en) | 1997-05-30 | 2004-09-15 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivatives |
| WO1999003880A1 (en) | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | Nociceptin analogues |
| US5929035A (en) | 1998-04-14 | 1999-07-27 | Regents Of The University Of Michigan | Methods of treating intestinal disorders |
| ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
-
1999
- 1999-06-25 MA MA25646A patent/MA26659A1/fr unknown
- 1999-06-28 TW TW088110899A patent/TW513424B/zh not_active IP Right Cessation
- 1999-07-05 EP EP99926688A patent/EP1102762B1/en not_active Expired - Lifetime
- 1999-07-05 HR HR970081A patent/HRP20010089B1/xx not_active IP Right Cessation
- 1999-07-05 JP JP2000563646A patent/JP3367945B2/ja not_active Expired - Fee Related
- 1999-07-05 DE DE69903953T patent/DE69903953T2/de not_active Expired - Fee Related
- 1999-07-05 HK HK02101444.8A patent/HK1040188A1/zh unknown
- 1999-07-05 CZ CZ2001397A patent/CZ2001397A3/cs unknown
- 1999-07-05 AU AU43859/99A patent/AU749166B2/en not_active Ceased
- 1999-07-05 IL IL14102999A patent/IL141029A0/xx unknown
- 1999-07-05 GE GEAP19995740A patent/GEP20033000B/en unknown
- 1999-07-05 AP APAP/P/2001/002063A patent/AP2001002063A0/en unknown
- 1999-07-05 TR TR2001/00403T patent/TR200100403T2/xx unknown
- 1999-07-05 BR BR9912778-4A patent/BR9912778A/pt not_active Application Discontinuation
- 1999-07-05 CN CN99810857A patent/CN1317968A/zh active Pending
- 1999-07-05 EE EEP200100075A patent/EE200100075A/xx unknown
- 1999-07-05 WO PCT/IB1999/001239 patent/WO2000008013A2/en not_active Ceased
- 1999-07-05 PT PT99926688T patent/PT1102762E/pt unknown
- 1999-07-05 NZ NZ509299A patent/NZ509299A/en not_active Application Discontinuation
- 1999-07-05 AT AT99926688T patent/ATE227716T1/de not_active IP Right Cessation
- 1999-07-05 SI SI9930151T patent/SI1102762T1/xx unknown
- 1999-07-05 HU HU0103567A patent/HUP0103567A3/hu unknown
- 1999-07-05 HN HN1999000105A patent/HN1999000105A/es unknown
- 1999-07-05 ID IDW20010284D patent/ID27212A/id unknown
- 1999-07-05 CA CA002339621A patent/CA2339621C/en not_active Expired - Fee Related
- 1999-07-05 TN TNTNSN99142A patent/TNSN99142A1/fr unknown
- 1999-07-05 SK SK160-2001A patent/SK1602001A3/sk unknown
- 1999-07-05 YU YU8201A patent/YU8201A/sh unknown
- 1999-07-05 EA EA200100104A patent/EA200100104A1/ru unknown
- 1999-07-05 DK DK99926688T patent/DK1102762T3/da active
- 1999-07-05 PL PL99346211A patent/PL346211A1/xx not_active Application Discontinuation
- 1999-07-05 ES ES99926688T patent/ES2185357T3/es not_active Expired - Lifetime
- 1999-07-05 OA OA1200100031A patent/OA11590A/en unknown
- 1999-07-06 AR ARP990103264A patent/AR018686A1/es active IP Right Grant
- 1999-07-15 PE PE1999000717A patent/PE20000868A1/es not_active Application Discontinuation
- 1999-07-16 SV SV1999000099A patent/SV1999000099A/es not_active Application Discontinuation
- 1999-07-16 PA PA19998477701A patent/PA8477701A1/es unknown
- 1999-08-05 US US09/369,208 patent/US6172067B1/en not_active Expired - Fee Related
- 1999-08-06 GT GT199900125A patent/GT199900125A/es unknown
- 1999-08-13 UY UY25659A patent/UY25659A1/es not_active Application Discontinuation
-
2001
- 2001-01-16 IS IS5812A patent/IS5812A/is unknown
- 2001-02-01 ZA ZA200100900A patent/ZA200100900B/xx unknown
- 2001-02-05 NO NO20010603A patent/NO20010603L/no not_active Application Discontinuation
- 2001-03-01 BG BG105301A patent/BG105301A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2185357T3 (es) | Compuestos 2-sustituidos-1-piperidil bencimidazol como agonistas del receptor orl1. | |
| PE20250071A1 (es) | Compuesto ciclico que contiene accion inhibidora selectiva en kras por sobre hras y nras | |
| RU2010106393A (ru) | Новые микробиоциды | |
| RU2012108622A (ru) | Пестицидные композиции | |
| AR000039A2 (es) | Compuestos de piridinosulfonamida sustituidos, composiciones herbicidas que los contienen, metodo para preparar estos compuestos y compuestosintermediarios. | |
| CO5300399A1 (es) | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| RU2012108617A (ru) | Пестицидные композиции, область техники, к которой относится изобретение | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| AR040679A1 (es) | Mezclas herbicidas de accion sinergica | |
| AR110366A1 (es) | Combinaciones de compuesto activo | |
| RU2009141185A (ru) | Инсектицидные производные арилизоксазолина | |
| AR056882A1 (es) | Derivados del fungicida n- cicloalquil- bencil- amida | |
| AR058404A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
| CO5150227A1 (es) | Compuestos de triazol y su utilizacion | |
| AR062080A1 (es) | Combinaciones de principios activos con propiedades insecticidas y acaricidas | |
| AR066162A1 (es) | Derivados fungicidas de n- cicloalquil -n- carboxamida- biciclica | |
| MX2009005219A (es) | Inhibidores macrociclicos del virus de hepatitis c. | |
| AR110367A1 (es) | Combinaciones de compuesto activo | |
| AR017902A1 (es) | UNA COMPOSICIoN FUNGICIDA Y UN PROCEDIMENTO PARA CONTROLAR HONGOS NOCIVOS CON DICHA COMPOSICIoN. | |
| AR037363A1 (es) | Derivados de indolil- y benzimidazolil-aminoacetonitrilo, composiciones para controlar parasitos y el uso de dichos compuestos para la preparacion de una composicion farmaceutica | |
| AR075664A1 (es) | Mezclas herbicidas | |
| CO5040073A1 (es) | Composiciones herbicidas de comprenden una tetrazolinona y un antidoto | |
| CO5550437A2 (es) | Compuestos quimicos | |
| CR7249A (es) | Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo |